Gary Rafaloff
Impact in
- Neurology top 5%
- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
-
- Nuclear Receptors and Signaling
- Nerve injury and regeneration
- Genetic Neurodegenerative Diseases
Papers in
-
- Chronic Myeloid Leukemia Treatments 2
-
- Nuclear Receptors and Signaling 1
- Co-authors
- Simon Stott (5 shared papers)Richard Wyse (7 shared papers)Kevin McFarthing (6 shared papers)Marco A. S. Baptista (2 shared papers)Leah Mursaleen (2 shared papers)Brian Fiske (4 shared papers)Sally Okun (1 shared paper)Johannes J. M. van Delden (1 shared paper)
- Journals
- Journal of Parkinson s Disease (6 papers)Neurology (2 papers)BMJ Open (1 paper)Journal of Medical Internet Research (1 paper)Movement Disorders (1 paper)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
Gary Rafaloff
9 papers receiving 347 citations
Gary Rafaloff's Hit Papers
Peers
Comparison fields: 5 of 58
- Neurology 189
- Cellular and Molecular Neuroscience 98
- Neurology 32
- Biological Psychiatry 6
- Physiology 11
Countries citing papers authored by Gary Rafaloff
This map shows the geographic impact of Gary Rafaloff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Rafaloff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Rafaloff more than expected).
Fields of papers citing papers by Gary Rafaloff
This network shows the impact of papers produced by Gary Rafaloff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Rafaloff. The network helps show where Gary Rafaloff may publish in the future.
Co-authors
The 25 scholars most cited alongside Gary Rafaloff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 102 | |
| 2 | 2022 | 76 | |
| 3 | 2023 | 57 | |
| 4 | Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update Hit paper breakdown → | 2024 | 54 |
| 5 | 2021 | 51 | |
| 6 | 2023 | 5 | |
| 7 | 2019 | 2 | |
| 8 | 2023 | 1 | |
| 9 | 2020 | 1 | |
| 10 | 2023 | 0 | |
| 11 | 2025 | 0 |
About Gary Rafaloff
Gary Rafaloff is a scholar working on Hematology, Cellular and Molecular Neuroscience, Neurology, Infectious Diseases and Organic Chemistry, having authored 11 papers that have together received 349 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (2 papers), Nuclear Receptors and Signaling (1 paper) and Parkinson's Disease Mechanisms and Treatments (1 paper). The work is most often cited by research in Neurology (189 citations), Cellular and Molecular Neuroscience (98 citations), Neurology (32 citations), Biological Psychiatry (6 citations) and Physiology (11 citations). Gary Rafaloff has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Simon Stott, Richard Wyse, Kevin McFarthing, Marco A. S. Baptista, Leah Mursaleen, Brian Fiske, Sally Okun, Johannes J. M. van Delden, Helen Matthews and Karen G. Raphael. Their work appears in journals such as Journal of Parkinson s Disease, Neurology, BMJ Open, Journal of Medical Internet Research and Movement Disorders.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.